Binding of Norwalk Virus-Like Particles to ABH Histo-Blood Group Antigens Is Blocked by Antisera from Infected Human Volunteers or Experimentally Vaccinated Mice by Harrington, P. R. et al.
JOURNAL OF VIROLOGY, Dec. 2002, p. 12335–12343 Vol. 76, No. 23
0022-538X/02/$04.000 DOI: 10.1128/JVI.76.23.12335–12343.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Binding of Norwalk Virus-Like Particles to ABH Histo-Blood Group
Antigens Is Blocked by Antisera from Infected Human
Volunteers or Experimentally Vaccinated Mice
Patrick R. Harrington,1 Lisa Lindesmith,2 Boyd Yount,2 Christine L. Moe,3 and Ralph S. Baric1,2*
Department of Microbiology and Immunology, School of Medicine,1 and Program in Infectious Diseases, Department of
Epidemiology, School of Public Health,2 University of North Carolina at Chapel Hill, Chapel Hill,
North Carolina 27599-7435, and Department of International Health, Rollins School
of Public Health, Emory University, Atlanta, Georgia 303223
Received 16 July 2002/Accepted 26 August 2002
Attachment of Norwalk (NV), Snow Mountain (SMV), and Hawaii (HV) virus-like particles (VLPs) to
specific ABH histo-blood group antigens was investigated by using human saliva and synthetic biotinylated
carbohydrates. The three distinct Norwalk-like viruses (NLVs) have various capacities for binding ABH
histo-blood group antigens, suggesting that different mechanisms for NLV attachment likely exist. Importantly,
antisera from NV-infected human volunteers, as well as from mice inoculated with packaged Venezuelan equine
encephalitis virus replicons expressing NV VLPs, blocked the ability of NV VLPs to bind synthetic H type 1,
Leb, and H type 3, suggesting a potential mechanism for antibody-mediated neutralization of NV.
Norwalk-like viruses (NLVs) are members of the family
Caliciviridae and are a leading cause of acute gastroenteritis
worldwide. Studies into the basic biology of NLVs have been
limited to recombinant molecular approaches and human chal-
lenge studies, primarily because no tissue culture model is
available and because an animal model for NLV infection has
only recently been reported (21). The genome of Norwalk virus
(NV), the prototype NLV, is a single-stranded, positive-polar-
ity RNA of approximately 7.5 kb in length and is organized into
three open reading frames (ORFs). The ORF2-encoded major
capsid protein self-assembles into Norwalk virus-like particles
(VLPs) when expressed from recombinant baculoviruses or
Venezuelan equine encephalitis virus (VEE) replicons in in-
sect or mammalian cells, respectively (3, 9, 11).
Marionneau et al. have recently reported that baculovirus-
expressed NV VLPs likely attach to either H types 1 or 3 on
gastroduodenal epithelial cells of secretor-positive individuals
(16). We describe a simple biochemical method to assess spe-
cific binding of three distinct VEE-expressed NLV VLPs to
various ABH histo-blood group antigens from the type 1 and 3
biosynthesis pathways. We also evaluated and compared the
receptor-blockade capacity of antisera from NV-infected hu-
man volunteers and from mice inoculated with two different
candidate vaccines.
Cloning, expression, and production of genogroup II NLV
VLPs. To assess the ability of different NLVs to bind ABH
histo-blood group antigens, Snow Mountain virus (SMV) and
Hawaii virus (HV) ORF2 capsid genes were cloned from the
stools of SMV- or HV-infected human volunteers (Fig. 1A).
HV1 is identical in amino acid sequence to the published HV
ORF2 (14), and the SMV1 consensus clone contains three
amino acid alterations (13).
HV1 and SMV1 capsid sequences were inserted into the
pVR21 VEE replicon vector, and packaged HV1- and SMV1-
carrying VEE replicon particles (VRPs) were produced as
previously described for NV1 (3). To determine if the VRPs
express NLV capsid proteins, baby hamster kidney (BHK) cell
cultures were infected with VRP-NV1, VRP-SMV1, or VRP-
HV1. Immunofluorescence analysis (IFA) with antiserum from
human volunteers challenged with either NV, SMV, or HV
demonstrated that all three capsid constructs were expressed
from the VEE replicons (Fig. 1B). Putative VLPs were har-
vested from VRP-infected BHK cell extracts and were purified
by ultracentrifugation through 20 to 50% continuous sucrose
gradients. As previously shown with NV (3, 9), negative-stain
electron microscopic analysis clearly revealed that the SMV
and HV capsid proteins self-assembled into VLPs (Fig. 1C).
Attachment of NLV VLPs to ABH histo-blood group anti-
gens. The ABH and Lewis histo-blood group antigens are
carbohydrate epitopes present throughout many tissues of the
human body (reviewed in reference 15). The type 1 and 3 chain
ABH histo-blood group antigens are present on mucosal epi-
thelial cell surfaces and in salivary secretions, with variations in
the carbohydrate milieu in different individuals based on their
secretor status and blood type (Fig. 2A). Recent observations
suggest that NV likely attaches to either H types 1 or 3 present
on gastroduodenal epithelial cells (16). To build upon these
observations and to determine if other NLVs attach to ABH
histo-blood group antigens, we examined whether NV, SMV,
or HV VLPs attach to secreted ABH histo-blood group anti-
gens in saliva. Human saliva samples were obtained and typed
for the presence of ABH antigens in relation to blood type and
secretor status by using antibodies to Lea, Leb, A antigen, and
B antigen (Ortho Clinical Diagnostics, Raritan, N.J.). All sam-
ples were from Lewis-positive individuals. Saliva samples were
boiled for 5 min prior to binding analysis to denature any
potential anti-NLV antibody. Plates were coated with boiled
saliva at a 1:500 dilution in carbonate buffer (pH 9.6) for 4 h at
ambient temperature and were blocked overnight in 5% milk
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FIG. 1. Expression and self-assembly of NLV capsid proteins. HV and SMV genomic RNA was isolated from the stools of SMV- or
HV-infected human volunteers. The capsid genes were isolated by reverse transcription-PCR and were subcloned into the pVR21 VEE replicon
vector as previously described for NV1 (3) with specific primer pairs 5-AGTCTAGTCCGCCAAGATGAAGATGGCGTCGAATGAC-3 and
5-NNNTTAATTAATTATTGCACTCTTCTGCGCC-3 (HV-5 and HV-3, respectively) for HV or HV-5 and 5-NNNNNNNGGCGCGCCT
TACTGAACCCTTCTACGC-3 (SMV-3) for SMV. (A) Amino acid (aa) alignment of NV, HV, and SMV ORF2 regions. NV is a genogroup
I isolate, whereas SMV and HV are genogroup II NLVs from distinct genogroup clusters (GII.2 and GII.1, respectively). Percentage of amino acid
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in Tris-buffered saline (TBS). NV, SMV, or HV VLPs (0.1 g)
were then added to saliva-coated wells in 1% milk–Tween-TBS
and were incubated for 1 h at 37°C. VLP binding was detected
by using convalescent antiserum from NV-, SMV-, or HV-
infected human volunteers and goat anti-human immunoglob-
ulin G (IgG) alkaline phosphatase conjugate. Plates were de-
veloped with p-nitrophenyl phosphate substrate (pNPP)
(Sigma-FAST tablets; Sigma, St. Louis, Mo.), and the optical
densities at 405 nm (OD405) were determined.
NV VLPs bound efficiently to saliva components from se-
cretor-positive (Se), blood type O, A, and AB individuals but
not to saliva from secretor-negative (Se) individuals (Fig.
2B). The fact that NV VLPs bound poorly to saliva containing
ABH antigens in blood group B individuals might also account
for the observation that blood group B individuals are more
resistant to NV challenge (10). SMV VLPs bound to saliva
from Se blood type B and AB individuals, suggesting that
SMV and NV attach to different ABH histo-blood group car-
bohydrates. Dose-dependent binding of SMV VLPs based on
B antigen expression was also evident (data not shown), sug-
gesting that SMV utilizes B type 1, B type 3, or another down-
stream carbohydrate for attachment. HV VLPs did not bind to
saliva components regardless of secretor phenotype or blood
type, suggesting yet a third possible mechanism for NLV at-
tachment. These data suggest that blood group and secretor
status may be susceptibility alleles for some, but not all, NLV
infections in humans.
To clearly identify which particular ABH histo-blood group
antigens are involved in NLV attachment, a microwell-based
assay was designed to biochemically detect and quantify levels
of synthetic, biotinylated ABH histo-blood group carbohydrate
binding to NLV VLPs. High-binding microwells were coated
with NLV VLPs or sucrose-purified transmissible gastroenter-
itis virus virions. The coated wells were incubated with serially
diluted, synthetic biotinylated ABH histo-blood group carbo-
hydrates as described in the legend to Fig. 3. Carbohydrate
binding was detected using a streptavidin-alkaline phosphatase
conjugate and substrate.
Neither NV, SMV, nor HV VLPs bound synthetic, biotinyl-
ated H type 1 precursor (Fig. 3A), which lacks the FUT2-
linked 1-2 fucose in H type 1. However, under identical con-
ditions NV VLPs, but not SMV or HV VLPs, clearly bound H
type 1 carbohydrate in a dose-dependent manner (Fig. 3B),
supporting the notion that different NLVs utilize different
pathways for docking and entry. NV VLPs also bound H type
3, although not as well as H type 1 (Fig. 3D). This interaction
is specific, as NV VLPs did not bind the H type 3 precursor
(Fig. 3C). SMV and HV VLPs did not detectably bind H type
3 or its precursor (Fig. 3C and D). Neither NV, SMV, nor HV
VLPs detectably bound Lea (Fig. 3E). However, NV VLPs
clearly bound synthetic Leb carbohydrate (Fig. 3F). Interest-
ingly, this is the first suggestion that Leb may function as a
target for NV attachment. The A, B, and FUT3 enzymes com-
pete for the common H type 1 substrate. Individuals of blood
type O do not maintain active A or B enzyme and will likely
retain more H type 1 substrate for subsequent FUT3 Lewis
enzymatic activity. Therefore, the interaction of NV VLPs with
Leb, but not Lea, agrees with the findings that saliva from
secretor-positive blood type O individuals binds NV VLPs and
that individuals of blood type O are most susceptible to NV
infection (10). Finally, we evaluated the ability of the VLPs to
attach to H type 2, which is present on red blood cells but is not
produced at the surfaces of the gastric mucosa or in salivary
secretions. Consistent with the tissue distribution of H type 2,
NV, SMV, and HV VLPs did not bind synthetic H type 2
carbohydrate (Fig. 3G).
To verify the carbohydrate binding results, the binding as-
says were repeated in microwells coated with 10 g of each
VLP stock/ml, which confirmed that the NV VLPs bound only
H type 1, H type 3, and Leb (data not shown). Also, although
the initial binding data suggest that HV might bind H type 1 at
relatively high carbohydrate concentrations (Fig. 3B), neither
HV nor SMV VLPs coated at 10 g/ml could detectably bind
any of the synthetic carbohydrates tested (data not shown).
To determine if the interaction of NV capsid proteins with H
type 1 depends on the ability of the proteins to self-assemble
into VLPs, the binding capacity of NV2 protein and heat-
denatured VLPs was evaluated. The NV2 capsid construct
contains three amino acid mutations from the wild type, which
collectively ablate the ability of the protein to self-assemble
into VLPs (3). Neither NV2 nor denatured NV1 VLPs could
detectably bind H type 1 (Fig. 3H). Also, with both the binding
assay described above and an NV VLP competition-based as-
say we were unable to detect any interaction of H type 1 with
a series of 15-mer overlapping peptides that span the entire
NV capsid protein (data not shown), confirming that H type 1
binding is dependent on VLP assembly.
Blockade of NV:ABH histo-blood group antigen binding by
antisera from infected human volunteers. One basic mecha-
nism by which viruses are neutralized is the antibody-mediated
prevention of viral attachment to host cells (4, 5, 18, 22).
Therefore, the development of an assay system that measures
antibody-mediated neutralization of virus binding to its recep-
tor would be valuable for NLV immunity and vaccine studies.
We utilized the carbohydrate binding assay to determine if
infection with NV stimulates antibody responses that block
attachment of NV to its putative receptor(s).
Human volunteers were dosed with 107 to 108 PCR-detect-
able units of the NV 8fIIb challenge inoculum. Infection in the
challenged volunteers based on seroconversion or PCR detec-
tion of virus in stool has been determined and will be described
in greater detail elsewhere (C. Moe, unpublished data). Ten
randomly chosen serum sample pairs from day 0 and days 21 to
23 postinfection (prechallenge and convalescent, respectively)
identities are shown, and arrows indicate amino acid variations from published sequences (12–14). The NV ORF2 capsid clone NV1 has been
previously described and is identical to the published NV ORF2 amino acid sequence (9, 12). (B) BHK cells were infected with packaged VRPs
encoding NV, SMV, or HV capsid proteins. Expression of NLV capsid proteins was determined by IFA with human antiserum directed to either
NV, SMV, or HV. After determination of the VRP titers by IFA as described previously (3, 9), BHK cells were infected with VRPs encoding either
NV, SMV, or HV capsid proteins at a multiplicity of infection of 2. At 36 h postinfection BHK cells were lysed by freeze-thaw and the extracts
were purified through sucrose gradients and were analyzed by negative-stain electron microscopic analysis (C). Scale bar, 100 nm.
VOL. 76, 2002 NOTES 12337
FIG. 2. Binding of NLV VLPs to saliva components from individuals of different blood types and secretor status. (A) General schematic of the
type 1 and 3 chain ABH histo-blood group antigen production pathways adapted from that described in reference 15. Synthetic carbohydrates used
in this paper are boxed. Enzymatic activities are in italics (FT, fucosyltransferase). The type 1 and 3 chains are the primary histo-blood group
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were obtained from volunteers determined to be infected. NV
VLP-specific serum IgG titers were quantified by enzyme-
linked immunosorbent assay (ELISA) (9), and all volunteers
had preexisting anti-NV antibody. Serum samples were serially
diluted and preincubated in NV VLP-coated microwells prior
to addition of the appropriate synthetic carbohydrate and com-
pletion of the binding assay as described above.
Convalescent human antisera, but not preinfection antisera,
efficiently blocked binding of H type 1 to NV VLPs (Fig. 4A).
The dilution (blockade titer) at which antisera could block 50
and 90% of the signal produced from H type 1:NV VLP bind-
ing (BT 50 and BT 90, respectively) was determined for each
sample (Fig. 4B). Of the 10 serum pairs, 3 preinfection samples
had detectable BT 50 titers, which might suggest prior expo-
sure to NV or a closely related NLV. In contrast, all convales-
cent antisera samples had BT 50 and BT 90 activity at sera
concentrations of 0.33%  0.17% and 1.13%  0.81%, respec-
tively. The 30-fold difference in BT 50 titers between the 3
preinfection and 10 convalescent-phase serum samples is sig-
nificant (P  0.005; Student’s t test). The blockade capacity
(BT 50) of the convalescent antiserum correlates with the
NV-specific IgG titer in the serum samples as determined by
ELISA (R2  0.9; linear trend analysis), whereas the blockade
titers of the preinfection serum samples do not correlate with
their respective anti-NV IgG titers (R2  0.5) (data not
shown). Convalescent antiserum from the infected volunteers
also inhibited the binding of NV VLPs with Leb and H type 3
(Fig. 4C and D).
Blockade of NV:ABH histo-blood group antigen binding by
antisera from experimentally vaccinated mice. Multiple-can-
didate VLP-based NLV vaccine strategies have been proposed
to date. Oral inoculation of baculovirus-expressed NV VLPs
stimulates systemic and mucosal antibody responses in mice
and boosts antibody responses in human volunteers previously
exposed to NV (1, 2, 7). It was recently demonstrated that
inoculation of mice with packaged VEE replicon particles ex-
pressing Norwalk VLPs stimulates robust systemic, mucosal,
and heterotypic antibody responses (9). However, the lack of a
convenient tissue culture or animal model for NLV infection
does not allow the use of conventional animal challenge or
tissue culture neutralization assays to evaluate the relative
effectiveness of any candidate NLV vaccine.
The synthetic carbohydrate binding assay was utilized to
identify potentially neutralizing antibody responses in mice
inoculated with the two candidate vaccines. Two groups of four
6-week-old male BALB/c mice were either inoculated with two
doses of the VRP-NV1 replicon construct or were orally dosed
with NV VLPs on days 0 and 23. Preimmune and day 35 blood
samples were collected by tail bleed, and serum anti-NV IgG
titers were determined by ELISA (9). Of the four mice orally
inoculated with NV VLPs, only one mouse had detectable
anti-NV IgG in the day 35 antisera (9). However, all four mice
inoculated with VRP-NV1 produced robust titers of anti-NV
serum IgG (data not shown), confirming our previous report
(9).
Day 35 antisera from all mice inoculated with VRP-NV1
blocked nearly 100% of H type 1:NV VLP binding with only
0.5% (1:200 dilution) preincubated serum (Fig. 5A). Based on
anti-NV IgG titers, the postinoculation mouse antisera was
5-fold more effective at blocking H type 1:NV VLP binding
than the human antisera (data not shown). Preimmune sera
from the same mice at concentrations as high as 10% did not
detectably block H type 1 binding (Fig. 5A and data not
shown). Antiserum from the single mouse that responded to
oral inoculation of NV VLPs did not appear to block binding
of H type 1 to the VLP-coated wells any better than preim-
mune serum from the same mouse (Fig. 5B). Day 35 antisera
from mice inoculated with VRP-NV1 also similarly blocked
Leb:NV and H type 3:NV binding (data not shown).
We have developed a simple biochemical assay that mea-
sures NV VLP binding to H type 1 and other ABH histo-blood
group antigens. These data build upon earlier observations (10,
16) and collectively suggest that Se individuals are more likely
to become infected with NV than Se individuals. Also, based
on saliva and carbohydrate binding assays with SMV and HV
VLPs, we’ve identified at least two potential additional mech-
anisms for NLV attachment, with one mechanism (HV) pos-
sibly not related to secretor phenotype or the ABH histo-blood
group antigens. This report warrants additional studies to fully
elucidate the extent and significance of ABH attachment of
NLVs and whether the carbohydrates act as primary receptors
or merely enhance NLV infectivity or attachment to a common
cellular receptor.
The experiments described in this manuscript may provide a
useful surrogate for examining and monitoring NLV neutral-
izing antibody as a result of viral infection or vaccination.
NV-challenged human volunteers that became infected
mounted robust serum IgG responses that efficiently blocked
carbohydrates present in saliva and on epithelial cell surfaces of the gastric mucosa, presumed to be the site of NLV attachment (16, 20). H antigens
are the first carbohydrates synthesized from precursor disaccharides by the enzymatic activity of the 1,2 fucosyltransferase encoded by either the
fut1 or fut2 gene. About 20% of the European population encodes a mutant form of the fut2 gene resulting in the nonsecretor phenotype.
Nonsecretors do not express a functional FUT2 enzyme and will thus not produce carbohydrates downstream of the H precursors (dashed line)
on gastric mucosal surfaces or in saliva. In secretors, the A or B enzyme expressed by blood type A or B individuals, respectively (or both in type
AB individuals), can further modify the H antigens along the particular type chain. Individuals of blood type O do not produce A or B enzymes
and therefore do not express A or B antigens or downstream carbohydrates on mucosal surfaces. The Lea and Leb antigens are synthesized by the
FUT3 Lewis enzymes (1-3/4 fucosyltransferases) from either the H type 1 precursor or H type 1, respectively. In saliva and in the gastric mucosa,
Lewis-positive secretors will generally produce Leb and relatively less Lea, whereas nonsecretors will only produce Lea. (B) Binding of NLV VLPs
to saliva from individuals of various secretor status and blood type. VLPs were added to saliva-coated microwells, and VLP binding was detected
with appropriate human anti-NLV antisera, anti-IgG alkaline phosphatase conjugated secondary antibody, and pNPP substrate. The OD405
quantifies net VLP binding to saliva after background subtraction, and the dashed line represents an arbitrary negative cutoff value equivalent to
twice the average background OD. Mean values from duplicate wells are shown, and error bars represent the standard deviation. The x axis displays
the individuals’ secretor phenotype and blood type. Note that saliva samples could only be obtained from one Se blood type B and no Se blood
type AB individuals.
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binding of NV VLPs with H type 1, H type 3, and Leb. Also,
immunization with VEE replicons expressing NV VLPs, but
not oral VLP inoculation, stimulated robust titers of attach-
ment-blocking serum antibody in mice. It is unclear at this
point if the anti-NV IgG titers in the orally inoculated mice are
simply insufficient to detect NV VLP:H type 1 blockade or if
the antibody does not recognize the appropriate H type 1
binding epitopes. Nevertheless, immunization with VEE rep-
licons expressing the NV VLPs stimulated considerably higher
titers of attachment-blocking antibody than oral inoculation of
the NV VLPs. We anticipate that the coadministration of a
mucosal adjuvant and/or intranasal inoculation of NV VLPs
would improve the production and detection of ABH:NV VLP
blocking antibody (2, 7, 19).
Studies into NV immune mechanisms are complicated by
the fact that anti-NV serum IgG cross-reacts with various other
NLV capsid proteins (8), and the NLV infection history of the
challenged volunteers is unknown. Therefore, it is not known
whether the preexisting anti-NV IgG in the challenged volun-
teers emerged from a previous infection with NV or merely
represents cross-reactive, nonneutralizing antibody that has
remained from a previous, alternative NLV infection. The
FIG. 4. Human antisera blockade of NV VLP:ABH histo-blood group attachment. Prechallenge and convalescent-phase serum samples were
obtained from 10 human volunteers infected with a live NV challenge inoculum. Sera were serially diluted and added to NV-coated microwells
prior to addition of synthetic, biotinylated carbohydrates and completion of the binding assay. (A) The OD405 was determined to measure H type
1:NV VLP binding in the presence of various concentrations of the preincubated, prechallenge, and convalescent human antisera. Results indicate
the mean OD405 from 10 human serum sample pairs, and error bars represent standard deviation. The dashed line represents 100% H type 1
binding (no preincubated serum). (B) The serum dilution (blockade titer) at which 50 and 90% H type 1 is blocked from binding to the NV VLPs
(BT 50 and BT 90, respectively) was determined on the basis of OD values. Results indicate the mean blockade titer of the serum samples, with
detectable BT 50 and BT 90 values at the concentrations tested, and the number of samples with detectable BT 50 or BT 90 titers is indicated by
parentheses. Error bars indicate blockade titer standard deviation from only those samples with detectable BT 50 and BT 90 values. (C and D)
Human antisera blockade of Leb:NV VLP and H type 3:NV VLP binding. Serum samples were preincubated with NV VLP-coated wells prior to
addition of the biotinylated carbohydrates and completion of the binding assay. Results indicate mean OD values for 10 serum pairs, and error
bars represent standard deviation.
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methods described in this study could provide a means for
detecting and measuring type-specific NLV neutralizing anti-
body to clarify our understanding of a patient’s NLV exposure
history. We hypothesize that the three individuals with pre-
challenge anti-NV IgG that partially blocked H type 1 binding
may have been recently exposed to NV or a genetically similar
NLV, whereas the anti-NV IgG in the other seven individuals
recognized cross-reactive epitopes and is indicative of prior
exposure to other NLV(s) but not NV.
Importantly, the mucosal immune response likely plays a
critical role in NLV immunity (6, 17, 19). Therefore, it is
important to determine whether the carbohydrate-blocking an-
tiserum is indicative of a protective antibody response in the
human volunteers. Examinations of receptor-blocking anti-
body in mucosal secretions and determining the potential func-
tion of both serum and mucosal receptor-blocking antibody are
needed to fully understand their significance in NLV immu-
nity.
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